anti-mycobacterium

By Targets:	ATP Synthase (1) Bacterial (9) Parasite (1)
By Research Areas:	Infection (9) Inflammation/Immunology (1) Metabolic Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1377

Nevadensin	Bacterial	Infection Metabolic Disease Inflammation/Immunology
Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 (hCE1) with an IC₅₀ of 2.64 μM. Nevadensin has a variety of pharmacological effects such as anti-mycobacterium tuberculosis activities, antitussive, anti-inflammatory and anti-hypertensive .

HY-135453

(-)-Pinocembrin	Bacterial	Infection
(-)-Pinocembrin exhibits *anti-mycobacterium* activity against mycobacteriuum tuberculosis H37Ra with an IC₅₀ value of 1.11 mg/mL in dormant phase and 1.21 mg/mL in active phase, respectively. (-)-Pinocembrin has potent antiproliferative activity with IC₅₀ values of 1.88-11.00 mg/mL against THP-1, A549, Panc-1, HeLa and MCF7 cell lines .

HY-113729

B 746

Bacterial Infection

B746 is a clofazimine analog with anti-Mycobacterium avium complex (MAC) activity and is less effective when used with clofazimine or streptomycin .

B 746	Bacterial	Infection
B746 is a clofazimine analog with anti-Mycobacterium avium complex (MAC) activity and is less effective when used with clofazimine or streptomycin .

HY-162328

Antibacterial agent 194	Bacterial	Infection
Antibacterial agent 194 (Compound 19) is an antibacterial agent. Antibacterial agent 194 has potent anti-Mycobacterium tuberculosis (anti-Mtb) activity (MIC = 1 μg/mL) .

HY-N10930

7-Oxo-ganoderic acid Z	Bacterial	Infection
7-Oxo-ganoderic acid Z, a terpenoid, is a nature product that could be isolated from Resina Commiphora. 7-Oxo-ganoderic acid Z has Anti-Mycobacterium tuberculosis activity .

HY-155722

Mtb-IN-5	Bacterial	Infection
Mtb-IN-5 (compound (-)17j) is an isoxazole, with anti-Mycobacterium tuberculosis (Mtb) activity. Mtb-IN-4 inhibits Mtb respiration and biofilm formation in macrophage, and enhances antibiotic isoniazid (INH) inhibition against INH-resistant Mtb mutant .

HY-155720

Mtb-IN-4	Bacterial	Infection
Mtb-IN-4 (compound 17h) is a nontoxic isoxazole, with anti-Mycobacterium tuberculosis (Mtb) activity (IC₅₀=0.70 μM). Mtb-IN-4 inhibits Mtb respiration and biofilm formation in macrophage, and enhances antibiotic isoniazid (INH) inhibition against INH-resistant Mtb mutant .

HY-146388

Mtb ATP synthase-IN-1	Bacterial ATP Synthase	Infection
Mtb ATP synthase-IN-1 (compound 6ab) is a potent Mycobacterium tuberculosis (Mtb) ATP synthase inhibitor, with MIC of 0.452-0.499 μg/mL against Mtb. Mtb ATP synthase-IN-1 has good metabolic stability, low cytotoxicity (Vero IC₅₀ > 64 μg/mL), and acceptable oral bioavailability. Mtb ATP synthase-IN-1 can be used for researching anti-mycobacterium .

HY-N2876

Anisofolin A	Parasite Bacterial	Infection
Anisofolin A is a flavonoid that can be isolated from Anisomeles indica. Anisofolin A has antimalarial activity (IC₅₀: 4.39 μM), and antimycobacterium activity (IC₅₀: 4.50 μM) against M. tuberculosis H37Ra .

Cat. No.	Product Name

HY-L142

Anti-tuberculosis Compound Library	94 compounds
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases. Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs. MCE supplies a unique collection of 94 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Anti-tuberculosis Compound Library

94 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 94 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1377

Nevadensin	Flavonoids other families Classification of Application Fields Flavones Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Inflammation/Immunology	Bacterial
Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 (hCE1) with an IC₅₀ of 2.64 μM. Nevadensin has a variety of pharmacological effects such as anti-mycobacterium tuberculosis activities, antitussive, anti-inflammatory and anti-hypertensive .

HY-135453

(-)-Pinocembrin	Structural Classification Flavonoids Flavones Polygonaceae Source classification Persicaria glabra (Willd.) M. Gomez Plants	Bacterial
(-)-Pinocembrin exhibits *anti-mycobacterium* activity against mycobacteriuum tuberculosis H37Ra with an IC₅₀ value of 1.11 mg/mL in dormant phase and 1.21 mg/mL in active phase, respectively. (-)-Pinocembrin has potent antiproliferative activity with IC₅₀ values of 1.88-11.00 mg/mL against THP-1, A549, Panc-1, HeLa and MCF7 cell lines .

HY-N10930

7-Oxo-ganoderic acid Z	Triterpenes Structural Classification Commiphora myrrha (Nees) Engl. Terpenoids Source classification Plants Burseraceae	Bacterial
7-Oxo-ganoderic acid Z, a terpenoid, is a nature product that could be isolated from Resina Commiphora. 7-Oxo-ganoderic acid Z has Anti-Mycobacterium tuberculosis activity .

HY-N2876

Anisofolin A	Structural Classification Monophenols Flavonoids Flavones Labiatae Source classification Phenols Plants Artemisia persica Boiss.	Parasite Bacterial
Anisofolin A is a flavonoid that can be isolated from Anisomeles indica. Anisofolin A has antimalarial activity (IC₅₀: 4.39 μM), and antimycobacterium activity (IC₅₀: 4.50 μM) against M. tuberculosis H37Ra .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Natural
Products

Name
Email *

	Sorry, but the email address you supplied was invalid.

anti-mycobacterium

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Natural
Products